Brief: FDA Grants Permission To Enroll Up To 8 Additional Secondary Progressive Multiple Sclerosis Patients In Expanded Access Program With Intranasal Foralumab
05/04/2022 12:06
April 5 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* FDA GRANTS PERMISSION TO ENROLL UP TO 8 ADDITIONAL
SECONDARY
PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN THE EXPANDED
ACCESS PROGRAM WITH INTRANASAL FORALUMAB
* TIZIANA LIFE SCIENCES - CLINICAL DATA UPDATE FROM SECOND
SPMS
PATIENT EXPECTED IN MAY 2022, REPRESENTING 3 MONTHS OF
INTRANASAL FORALUMAB THERAPY
Source text for Eikon: ID:nGNX317Hfl
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis